Literature DB >> 26938573

Practice Bulletin No. 162: Prenatal Diagnostic Testing for Genetic Disorders.

.   

Abstract

Prenatal genetic diagnostic testing is intended to determine, with as much certainty as possible, whether a specific genetic disorder or condition is present in the fetus. In contrast, prenatal genetic screening is designed to assess whether a patient is at increased risk of having a fetus affected by a genetic disorder. Originally, prenatal genetic testing focused primarily on Down syndrome (trisomy 21), but now it is able to detect a broad range of genetic disorders. Although it is necessary to perform amniocentesis or chorionic villus sampling (CVS) to definitively diagnose most genetic disorders, in some circumstances, fetal imaging with ultrasonography, echocardiography, or magnetic resonance imaging may be diagnostic of a particular structural fetal abnormality that is suggestive of an underlying genetic condition.The objective of prenatal genetic testing is to detect health problems that could affect the woman, fetus, or newborn and provide the patient and her obstetrician-gynecologist or other obstetric care provider with enough information to allow a fully informed decision about pregnancy management. Prenatal genetic testing cannot identify all abnormalities or problems in a fetus, and any testing should be focused on the individual patient's risks, reproductive goals, and preferences. It is important that patients understand the benefits and limitations of all prenatal screening and diagnostic testing, including the conditions for which tests are available and the conditions that will not be detected by testing. It also is important that patients realize that there is a broad range of clinical presentations, or phenotypes, for many genetic disorders and that results of genetic testing cannot predict all outcomes. Prenatal genetic testing has many benefits, including reassuring patients when results are normal, identifying disorders for which prenatal treatment may provide benefit, optimizing neonatal outcomes by ensuring the appropriate location for delivery and the necessary personnel to care for affected infants, and allowing the opportunity for pregnancy termination.The purpose of this Practice Bulletin is to review the current status of prenatal genetic diagnostic testing and the evidence supporting its use. For information regarding screening for fetal aneuploidy, refer to Practice Bulletin No. 163, Screening for Fetal Aneuploidy.

Entities:  

Mesh:

Year:  2016        PMID: 26938573     DOI: 10.1097/AOG.0000000000001405

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  45 in total

1.  Women's preferences for and experiences with prenatal genetic testing decision making: Sociodemographic disparities in preference-concordant decision making.

Authors:  Fabiola Molina; Christine Dehlendorf; Steven E Gregorich; Miriam Kuppermann
Journal:  Patient Educ Couns       Date:  2018-10-29

Review 2.  Prenatal Counseling of Fetal Congenital Heart Disease.

Authors:  Caroline K Lee
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-01

3.  The Effect of Religious Belief on the Attitudes of Pregnant's Toward the Fetal Health.

Authors:  Emre Demir; Engin Yıldırım
Journal:  J Relig Health       Date:  2019-12

4.  Investigating Pregnancy Outcomes After Abnormal Cell-Free DNA Test Results.

Authors:  Jessica Lu; Devereux N Saller; Luanne M Fraer; Beatrice A Chen
Journal:  J Genet Couns       Date:  2018-01-24       Impact factor: 2.537

Review 5.  Screening for fetal chromosomal and subchromosomal disorders.

Authors:  Sarah Harris; Dallas Reed; Neeta L Vora
Journal:  Semin Fetal Neonatal Med       Date:  2017-11-08       Impact factor: 3.926

6.  Maternal iAMP21 acute lymphoblastic leukemia detected on prenatal cell-free DNA genetic screening.

Authors:  Marlise R Luskin; Marie N Discenza; Sarah Rae Easter; Paola Dal Cin; Renius Owen; Bernard Ilagan; Meredith Masiello; Andrew A Lane
Journal:  Blood Adv       Date:  2017-08-15

7.  Comparison of indications and results of prenatal invasive diagnostic tests before and after the implementation of the use of cell-free fetal DNA: a tertiary referral center experience.

Authors:  Firat Okmen; Huseyin Ekici; Ismet Hortu; Metehan Imamoglu; Duygu Arican; Haluk Akın; Sermet Sagol
Journal:  J Assist Reprod Genet       Date:  2020-05-21       Impact factor: 3.412

8.  Complications in pregnant women with sickle cell disease.

Authors:  Kim Smith-Whitley
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 9.  Prenatal diagnosis by chromosomal microarray analysis.

Authors:  Brynn Levy; Ronald Wapner
Journal:  Fertil Steril       Date:  2018-02       Impact factor: 7.329

Review 10.  Genomic medicine for undiagnosed diseases.

Authors:  Anastasia L Wise; Teri A Manolio; George A Mensah; Josh F Peterson; Dan M Roden; Cecelia Tamburro; Marc S Williams; Eric D Green
Journal:  Lancet       Date:  2019-08-05       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.